跳到正文
原文
MedPage Today·· 13 天前AI 评分55

Lp(a)降低药物pelacarsen在心血管疾病预防中的效果有限

Lp(a)-Lowering Pelacarsen Shows Huge Disconnect With Cardiovascular Outcomes

AI 导读

Lp(a)降低药物pelacarsen在心血管疾病预防中的效果有限,HR为1.02,无显著改善。研究者认为这并不否定Lp(a)作为心血管风险因素的潜力,未来仍需更多数据支持。

正文

— After disappointing Lp(a) HORIZON trial, eyes turn to next-gen siRNA therapies

by Nicole Lou, Senior Staff Writer, MedPage Today

November 7, 2026 • 4 min read

Lowering lipoprotein(a), or Lp(a), did not translate into better cardiovascular outcomes in a secondary prevention population, at least not with pelacarsen in the Lp(a) HORIZON trial.

Among people with elevated lipoprotein(a) and pre-existing cardiovascular disease (CVD), pelacarsen was no help for reducing the primary endpoint of cardiovascular death, nonfatal stroke, nonfatal myocardial infarction (MI), or urgent coronary revascularization over nearly 5 years (HR 1.02 compared with placebo, 95% CI 0.90-1.15), reported Steven Nissen, MD, of the Cleveland Clinic, at the American Heart Association (AHA) annual meeting in Chicago.

No matter how the investigators sliced and diced the data, it was the same story: analysis of people with especially high lipoprotein(a), 90 mg/dL or higher, also yielded no benefit (HR 1.00, 95% CI 0.87-1.15); pelacarsen similarly showed no efficacy regarding a modified cardiovascular endpoint not counting revascularizations, another composite endpoint including coronary heart disease rather than cardiovascular deaths, and the individual outcomes of MI, stroke, urgent revascularization, and cardiovascular death.

Beyond these "completely neutral" results, "tolerability issues were certainly very prominent" with pelacarsen, Nissen added during an AHA press conference, citing rates of adverse events leading to drug discontinuation of 20.6% with pelacarsen versus 7.5% with placebo.

Nissen stressed that it may be the end of the road for pelacarsen, but not the lipoprotein(a) hypothesis.

"The Lp(a) HORIZON trial is not the end of the story. Ongoing trials are studying different populations, like primary prevention, aortic stenosis, and different therapies, and siRNA, several siRNAs. A single trial does not provide definitive evidence of a lack of benefit of lowering lipoprotein(a) as a strategy to reduce cardiovascular risk," he said.

Lipoprotein(a) is a genetically determined risk factor for atherosclerotic CVD and aortic stenosis. It is a highly atherogenic particle considered unmodifiable with diet or physical activity, unlike LDL cholesterol. Estimates suggest one in five people worldwide have high lipoprotein(a).

Pelacarsen was an antisense oligonucleotide made to degrade the hepatic mRNA coding for apolipoprotein(a), an intermediate to the production of lipoprotein(a).

In Lp(a) HORIZON, pelacarsen did drastically reduce lipoprotein(a) and LDL cholesterol by an estimated 77.7% and 13.3%, respectively, relative to placebo. This was on top of existing secondary prevention therapies that had gotten baseline LDL cholesterol to a median 64.6 mg/dL and systolic blood pressure to 125 mmHg on average.

"Was there no room left for improvement? To the credit of the investigators, what was done was actually optimization of what we know to do already: optimize the LDL, optimize the blood pressure. If we do that, was there just no room left in these patients to further reduce the risk?" posed panelist Donald Lloyd-Jones, MD, ScM, of Boston University.

"Like Dr. Nissen, I personally would not recommend that we abandon considering Lp(a) as a potential causal risk factor or as a therapeutic target until we have a lot more data available in different patient populations, certainly in younger individuals and primary prevention populations, over longer periods of time and with ... different chemical strategies to try to inhibit this molecule," said Lloyd-Jones, a past president of the AHA.

Nissen noted that the siRNA therapies in development are potentially more tolerable and more effective while requiring less frequent administration. Already advancing to large-scale cardiovascular outcome trials, for example, are lepodisiran and olpasiran, with others further back in the pipeline.

There's also evidence that the now-familiar PCSK9 monoclonal antibodies reduce Lp(a) along with LDL cholesterol, which may partly explain some of their benefit in CVD risk reduction, according to Lloyd-Jones.

"We don't fully understand the biology here, and I think we need to continue to take a deeper dive into that biology so that we fully understand what it is about Lp(a) that serves as a marker of risk and potentially as a better target for our future therapies," he said.

"I really think you cannot close the door with a single negative trial," Nissen emphasized. "It's going to be my mission to try to convince the people that pay the bills, which is industry sponsors, not to pull the plug on trials because we really need to understand more."

Lp(a) HORIZON trial was a phase III cardiovascular outcomes trial conducted in nearly 800 sites in 42 countries. Eligible participants had a cardiovascular event 3 months to 10 years prior to enrollment and lipoprotein(a) levels 70 mg/dL or greater. They underwent a risk factor optimization period to ensure use of secondary prevention therapies.

Nissen's group had 8,350 individuals randomized 1:1 to pelacarsen 80 mg or placebo self-administered once monthly subcutaneously.

Mean age was just under 60, with about 27% of participants being women and 78% white. Median lipoprotein(a) was 236 nmol/L and hsCRP 0.8 mg/L. Nearly 80% of the cohort were on high-intensity statins.

Follow-up reached a median 57 months in the trial.

Nissen reported that his group sought to conduct additional exploratory analyses on account of the "unexpected" results of Lp(a) HORIZON.

In this extension report, there was still no argument to be made for pelacarsen's efficacy even after accounting for treatment adherence, first and repeated adverse events, and magnitude of 3-month lipoprotein(a) reductions, among other analyses.

Lp(a) HORIZON trial was simultaneously published in the New England Journal of Medicine and its extension report separately released in NEJM Evidence.

来源:MedPage Today · medpagetoday.com